The role of the health and care workers in reducing medication errors and medication-related harm

Pharmacists

Ms Zuzana KUSYNOVÁ
Lead for Policy, Practice and Compliance
International Pharmaceutical Federation (FIP)

15 September 2022
The role of pharmacists in reducing medication errors and medication-related harm

Zuzana Kusynová
Lead for Policy, Practice and Compliance
FIP’s commitment
Long term partnership with WHO

Technical work

Policy work
FIP Statement of policy

Patient safety

FIP’s commitment to patient safety & recommendations for:

- Practicing pharmacists
- Pharmaceutical scientists
- National pharmacy organisations
- Industry partners
- Academia and educators

Adopted by 140+ pharmacy organisations around the globe
Minimising avoidable harm:

✓ Using the evidence to implement just culture

✓ Collaborating with other health professional associations to implement interprofessional strategies to foster close working relationships

✓ Developing educational tools to support appropriate pharmacist workforce development and safety culture

✓ Developing new services and health programmes while securing appropriate remuneration models

✓ Advocating for access to patient medication history

✓ Empowering and engaging patients to ‘Know, Check, Ask’ about their medications

✓ Advocating locally and globally for the importance of pharmacists in patient safety

Pharmacists can improve patient safety by promoting patient engagement, interprofessional collaboration and a safety culture to reduce avoidable harm caused by medication errors
Patient and Medication Safety

Recommendations

Minimising avoidable harm:
✓ Using the evidence to implement just culture
✓ Collaborating with other health professional associations to implement interprofessional strategies to foster close working relationships
✓ Developing educational tools to support appropriate pharmacist workforce development and safety culture

Minimising avoidable harm:
✓ Developing new services and health programmes securing appropriate remuneration models
✓ Advocating for access to patient medication
✓ Empowering and engaging patients to ‘Know, Check, Ask’ about their medications
✓ Advocating locally and globally for the importance of pharmacists in patient safety

Pharmacists can improve patient safety by promoting patient engagement, interprofessional collaboration and a safety culture reduced by medication errors
Minimising preventable harm

Pharmacists’ role

Pharmacists are well-positioned to minimise safety risks related to the entire medication use process by:

- Safeguarding accurate supply of medicines
- Validating appropriateness of prescription at initiation of treatment
- Ensuring correct medication use: drug-drug/food interaction and adherence barriers, educating patient
- Assisting interdisciplinary teams during the medication selection, use and follow-up
- Warranting safety in transitions of care between health care units and the community
Pharmacists are well-positioned to minimise safety risks related to the entire medication use process by:

- Minimising preventable harm
- Warranting safety in transitions of care between health care units and the community
- Assisting interdisciplinary teams during the medication selection, use and follow-up
- Ensuring correct medication use: drug-drug/food interaction and adherence barriers, educating patients
- Validating appropriateness of prescription at initiation of treatment
- Safeguarding accurate supply of medicines

- Individual patient level: medication journey, role as patient advocates and members of health care teams;
- Evidence of the positive impact;
- Parallels with other “safe” industries;
- Changes needed in the health care systems and practices: redesigning systems or services collaboratively between all key stakeholders;
- Mapping exercise: Case studies from 8 countries

Available from: fip.org/publications
Promoting a Safety Culture

"Blame Culture"

- Individuals responsible blamed & suffer consequences → encourages covering up of errors in fear of retribution.

"Safety/Just Culture"

- Focuses on identifying system flaws that can be resolved
- The goal is promoting patient safety
- An integrated pattern of individual and organizational behavior
FIP Resources
Toolkits for practitioners
Conclusions

Commitment of pharmacists

- Pharmacists are in a unique position to address the challenges related to medication use.
- They are well-positioned to minimise safety risks related to the entire medication use process.
- Pharmacists can improve patient safety by promoting patient engagement, interprofessional collaboration and a safety culture to reduce avoidable harm caused by medication errors.
- FIP is representing voices of over 4 million pharmacists around the globe – visible commitment through collaboration with partners, and at supporting pharmacists both at individual and systems/policy level.

#WPSD2022
Questions?
Message on World Patient Safety Day 2022 from the WHO Regional Office for the Eastern Mediterranean

Dr Ahmed AL-MANDHARI
WHO Regional Director for Eastern Mediterranean

15 September 2022
Session 3

Medication safety: medicines as products

Chair: Dr Shanthi PAL
Team Lead
Pharmacovigilance, Regulation and Prequalification department
WHO headquarters, Geneva

15 September 2022
Naming, labelling and packaging solutions to avoid LASA errors

Prof Hisham S. AL JADHEY
Executive President
Saudi Food & Drug Authority
Saudi Arabia

15 September 2022
SFDA Naming, Labelling and Packaging Solutions to Avoid Medication Errors

Prof. Hisham Aljadhey
Executive President of Saudi Food & Drug Authority (SFDA) Saudi Food and Drug Authority
Outline

- Medication Error Definition
- Medication Errors Department Activities in Medication Naming, Labelling and Packaging to Avoid Medication Errors
- Pre-Registration
- Post-Registration
Medication Error
Definition

“A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing, order communication, product labeling, packaging, and nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use.”

The National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)
<table>
<thead>
<tr>
<th>Invented Names Evaluation</th>
<th>Product labels/labeling</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Product packaging</td>
<td>Postmarket Pharmacovigilance</td>
</tr>
</tbody>
</table>
WHO Global
Patient Safety Challenge
Role of SFDA in preventing Medication Errors

- **Pre-Registration**
  - Naming Evaluation
  - Packaging Evaluation

- **Post-Registration**
  - Variation Requests
  - Reporting
  - Published Reports
Pre-Registration Activities
SFDA Guidance for Naming of Medicinal Products
- Assessment for any error-prone attributes
- Best practices for invented names design
- Misleading/promotional concerns
- Medicinal characteristics-related attributes
- Name similarity evaluation including generic names

International Nonproprietary Names (INN) Stem Book 2018
(WHO)/United States Adopted Names (USAN) approved stems
Saudi Naming Registration (SNR)/SFDA Drugs List
- Phonetic and Orthographic Computer Analysis (POCA)
- WHODrug Insight
- Martindale: The Complete Drug Reference
- Micromedex
- Lexicomp
Name Similarity Evaluation: A Look at Product Characteristics

- Active ingredient
- Strength
- Dosage form
- Route(s) of administration
- Indication
- Frequency
Acceptance vs. Rejection Rate
of Proposed Invented Names (Calendar Year 2021)

- Accepted: 71% (300 of 415)
- Rejected: 29% (121 of 415)
## Safety Concerns Associated with Rejected Proposed Invented Names

<table>
<thead>
<tr>
<th>Issue Description</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name Similarity</td>
<td>73</td>
<td>47.7%</td>
</tr>
<tr>
<td>Incorporation of International Nonproprietary Names Stem</td>
<td>24</td>
<td>15.7%</td>
</tr>
<tr>
<td>Promotional/Misleading Names</td>
<td>15</td>
<td>9.8%</td>
</tr>
<tr>
<td>Inappropriate Use of Qualifiers</td>
<td>13</td>
<td>8.5%</td>
</tr>
<tr>
<td>Inappropriate Use of Company Name</td>
<td>8</td>
<td>5.2%</td>
</tr>
<tr>
<td>Inclusion of Dosage form/Frequency/Strength</td>
<td>6</td>
<td>3.9%</td>
</tr>
<tr>
<td>Use of Abbreviations</td>
<td>5</td>
<td>3.3%</td>
</tr>
<tr>
<td>Name Discrepancies in Submitted Files</td>
<td>4</td>
<td>2.6%</td>
</tr>
<tr>
<td>Indication Derived Names</td>
<td>3</td>
<td>2.0%</td>
</tr>
<tr>
<td>Use of Ambiguous Numbers</td>
<td>2</td>
<td>1.3%</td>
</tr>
</tbody>
</table>
SFDA Guidance for Graphic Design
- of Medication Packaging
- Artwork Catalogue
- Country of origin packaging
# Naming Evaluation Look-Alike Names and Tall Man Lettering

<table>
<thead>
<tr>
<th>Prescribed</th>
<th>Given</th>
<th>Adverse Drug Event (ADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>HYDROmophine</td>
<td>Respiratory Arrest, Death</td>
</tr>
<tr>
<td>ChlorproMAZINE</td>
<td>ChlorproPAMIDE</td>
<td>Anoxic Brain damage from sustained hypoglycemia</td>
</tr>
</tbody>
</table>
Packaging Evaluation Cont.
Color Differentiation among different strengths
Importance of Med Error Reporting

Providing knowledge & updates of medication errors to boost activities in both pre & post marketing
How to Report SFDA Call center 19999
The safety of opioid medications: practical action at a system level

Mr Ewan MAULE
Director of Medicines and Pharmacy
North-East and North Cumbria
Integrated Care Board
UK

15 September 2022
Tackling the opioid crisis: one region’s experience

Ewan Maule
Director of Medicines and Pharmacy

WHO World Patient Safety Day Sept 2022
Global scale of the opioid crisis

Worldwide, about 0.5 million deaths are attributable to drug use, both prescribed and illicit.

More than 70% of these deaths are related to opioids.

‘The epidemic of opioid addiction and its consequences touch every community, every demographic and every single one of us in some way.’

- John Suthers – Colorado Attorney General
How a patient can suffer avoidable harm from opioids

- Faye, a 28 year old woman, sustained a back injury lifting a heavy object at home
- Two years later she had surgery to try to resolve the problem
- Oxycodone was given post operatively as 80mg a day (morphine equivalent 160mg)
- Faye’s continuing chronic pain was treated with higher and higher doses of oxycodone
- Four years on from the original injury Faye was taking a cocktail of drugs including
  - oxycodone, gabapentin, amitriptyline, sertraline, diclofenac and paracetamol
- She developed a range of symptoms including huge weight gain, sleep apnoea and depression
- A late stage introduction of cognitive behavioural therapy brought some improvement, but she tragically died with a respiratory arrest at the age of 32 years

Opioid deaths in the North East of England are higher and rising faster than the rest of the country.

1. https://www.who.int/initiatives/medication-without-harm
2. https://jamanetwork.com/journals/jama/fullarticle/2757570
A single agency approach to opioid harm will not work
A public facing campaign to tackle opioid harm
Progress with the opioid harm reduction programme over five years

30% reduction in overall opioid use

50% reduction in high dose opioid use
It may be a crisis, but lives can be and are being saved

• It’s taken me five years to get to where I am now. I understand I can live with some pain in my life. I was looking for the magic pill that does not exist. By accepting that the painkillers were doing more harm than good, that they were actually at the root of many of my problems, I am now in a much better place.

• I’ve lost 8 ½ stone. I walk most days. Everything starts to hurt more when I stay still, so the solution is to be more active. I’m a better mum because I’m present. I’m much more social, I love listening to music and when my restless legs kick in, well, I turn up the music and have a dance instead of turning to pills that stopped working a long time ago.

Louise Trewern
@Loulouscorpio
Product quality and Safety: scale of the problem and solutions – substandard and falsified medical products

Mr Rutendo KUWANA
Team Lead
Regulation and Safety
WHO headquarters
Geneva

15 September 2022
Product quality and safety: scale of the problem and solutions for substandard and falsified medical products

15 September 2022

Rutendo KUWANA
“Some falsified products are also being sold as vaccines on the internet, especially on the dark web.....we are aware of other reports of corruption and re-use of empty vaccine vials. We urge the secure disposal or destruction of used and empty vaccine vials to prevent them from being reused by criminal groups.

And we urge all people not to buy vaccines outside government-run vaccination programmes. Any vaccine bought outside these programmes may be substandard or falsified, with the potential to cause serious harm.

WHO regularly issues global medical product alerts on substandard and falsified products, and we will do so when and if necessary for COVID-19 vaccines and therapeutics.

We urge all countries and individuals to pay careful attention to this issue. Any suspicious sale of vaccines should be reported to national authorities, who will report it to WHO. Information flow is essential to map global threats and protect confidence in vaccines”
SF medical products – scale of the problem

- Undermine all global public health investments through treatment failure or harm to patients
- Antimicrobial resistance
- Damage trust in public systems
- Increase out-of-pocket spending
- Increase morbidity and mortality
- lost income and increased poverty, etc.

10.5% Observed failure rate on medicines samples in LMICs

286'000 annual deaths for childhood pneumonia and malaria

US$ 30.5 billion Estimated annual spending on SF medicines in LMIC
A holistic strategy to address a cross cutting issue
WHO’s dual approach

Political, operational and technical response

- Influence change in health and governance systems
- Technical and operational support to countries to prevent-detect-respond to SF medical products
- Various services e.g. global medical product alerts based on reports and analysis of the global surveillance & monitoring system
- Facilitate effective collaboration through the Member State mechanism
- Provide validated evidence base to guide policy and regulatory capacity building
The Global Surveillance and Monitoring System for substandard / falsified (SF) medical products

What is in it?

- Confirmed or suspected Falsified medical products
- Unexpected Adverse Reactions caused by medical products – including lack of efficacy
- Stolen medical products or products removed from the regulated supply chain

Why report?

- Product and batch may have already been reported by another Country
- The product may pose a risk to public health, perhaps in another country or region
- The product may have already undergone laboratory analysis - which can be shared
- Another country may be investigating the origin of the product and have helpful information
WHO Member State Mechanism

Established by World Health Assembly Resolution 65.19 to address SF medical products

Led by a Steering Committee chaired by Australia and supported by 11 Vice Chairs from all WHO Regions

WHO Member States agree on a 2-year workplan; current prioritized activities are for 2022-2023 and include work on:

- Regulatory capacity-building for prevention, detection and response
- Global networks
- Detection technologies and traceability
- Competencies and good governance
- Risk communication
- Impact and awareness
- Internet distribution and sale
- Informal markets

“The goal of the Member State Mechanism is to protect public health and promote access to affordable, safe, efficacious, and quality medical products, and to promote through effective collaboration among Member States and the Secretariat, the prevention and control of substandard and falsified medical products and associated activities.”
Message on World Patient Safety Day 2022 from the WHO Regional Office for Africa

Dr Matshidiso MOETI
WHO Regional Director for Africa

15 September 2022
BREAK
Session 4

Medication safety: systems and practices

Chair: Mr Frank FEDERICO
Faculty for Institute for Healthcare Improvement (IHI)
Senior Safety Expert

15 September 2022
Reducing patient harm through safe medication use process – focusing on prescribing, administration and monitoring

Ms Carolyn HOFFMAN
Chief Executive Officer
Institute for Safe Medication Practices
Canada (ISMP-Canada)

15 September 2022
"Medications are the most widely utilized interventions in health care, and medication-related harm constitutes the greatest proportion of the total preventable harm due to unsafe care, let alone the economic and psychological burden imposed by such harm."

World Health Organization, 2022

April 2012 feature article: https://thewalrus.ca/the-errors-of-their-ways/
A complex system...
“Just telling doctors and nurses to be more careful won’t do much. We need to change the systems that allow errors to happen.”

Dr. James Bagian
Anesthesiologist and Astronaut
5 Stages of Medication Use

- Prescribing
- Order Entry or Transcribing
- Dispensing
- Administration
- Monitoring
The Hierarchy of Intervention Effectiveness

Low Leverage
- Rules and policies (e.g., policies to prohibit borrowing doses from other areas)
- Education and information (e.g., education sessions on high-alert medications)

Medium Leverage
- Simplification and standardization (e.g., standardized paper or electronic order sets)
- Reminders, checklists, double checks (e.g., independent double checks for high-alert medications)

High Leverage
- Forcing functions and constraints (e.g., removal of a product from use)
- Automation or computerization (e.g., automated patient-specific dispensing)

Designing Effective Recommendations, ISMP Canada (2013)
Reduce the risk of prescribing errors

- Have essential patient information (e.g. age, weight, allergies, lab results)
- Use clinical decision support resources to inform evidence-based decisions
- Use computerized prescriber order entry
- Engage the patient/family so they can KNOW about their medications, CHECK for accurate dispensing / administration, monitor for ongoing safety, and ASK questions

Remember that abbreviations, symbols and dose designations can be error prone – comply with ‘Do Not Use’ lists

ISMP Canada - [https://ismpcanada.ca/resource/do-not-use-list/](https://ismpcanada.ca/resource/do-not-use-list/)
ISMP - [https://www.ismp.org/recommendations/error-prone-abbreviations-list](https://www.ismp.org/recommendations/error-prone-abbreviations-list)
Reduce the risk of administration errors

- Practitioners at the bedside play a key role in preventing errors
- Implement TALLman lettering for medications that may be confused, particularly look-alike/sound-alike (LASA) meds
- Implement independent double-checks for high-alert medications
- Verify the correct patient with 2 patient identifiers
- Use barcode-assisted medication administration technology
- Engage the patient/family in verifying medications so they can be a partner in their safety
Reduce the risk of monitoring errors

- Ensure all healthcare providers on the team know:
  - what measures will be taken to monitor the patient following administration of high-risk medications, and
  - what assessment results will trigger required action (e.g. blood glucose testing, sedation monitoring, INR monitoring)

- Integrate monitoring protocols into workflow design and health record documentation

- Engage the patient and family in the monitoring plan and results so they can be a partner in their safety
Reduce errors across all stages of medication use

✓ Use standardized order sets and standardized concentrations of medications wherever possible and integrate across prescriber and pharmacy systems, IV pump libraries, and monitoring records

✓ Make errors visible, use a systems approach to analyzing errors locally, integrate learning from others, and take action
Thank you!

Carolyn Hoffman, CEO
Carolyn.hoffman@ismpcanada.ca

ZERO Preventable Harm From Medications
Institute for Safe Medication Practices Canada
Challenges of reducing medication errors in primary, ambulatory, residential and home care

Prof Jose M VALDERAS
Chairman, WONCA Working Party
In Quality & Safety

15 September 2022
Critically different, increased challenges, opportunities

- Professional roles and scope of practice:
  - continuous (rather than episodic)
  - whole person oriented (rather than disease/problem oriented)
  - comprehensiveness
  - critical role in care coordination
    - high risk situations
    - polypharmacy
    - transitions

- Setting
  - less technology intensive
  - interface with multiple different settings
  - range of arrangements:
    - less hierarchized
    - less standardised (across settings)
Critically different, increased challenges, opportunities

- Patient and family
  - knowledge of patients
  - ongoing personal relationships
  - case-mix range: signal to noise ratio
- Medications
  - range of medications:
    - medication specific
    - interactions
High risk situations

Specific groups
- young children
- frail patients and those with cognitive impairment
- those living alone

Specific medications
- Antibiotics
- Insulin
- Narcotics
- Heparin and anticoagulants

Tools and technologies
- high-alert medications

Patient and family empowerment
Polypharmacy

- Integrating care as provided by multiple specialists and settings
- Increased uncertainty about risks and benefits
- Medication history
- Medication reviews
- Tools and technologies
- Patient and family empowerment
Transitions of care
Transitions of care

- Multiple interfaces
- Multiple multidisciplinary teams
- Medication reconciliation
- Tools and technologies
- Patient and family empowerment
Key role of Family Medicine

- At the intersection of high risk, polypharmacy and transitions
- Whole patient orientation and life course approach
  - Not just about the condition or the indication or the strength of evidence for a given pharmacological treatment
  - “Will THESE medications help THIS patient?”
- Partner with patients and families
Key role for Primary Care

- Need for settings and level specific evidence
- High quality primary care as a pre-requisite
- Monitoring of medication safety in primary care
  - OECD PaRIS Project
Thank you

All images from WHO documents of the Medication Without Harm series
The Economics of Medication Safety:
Improving medication safety through collective, real-time learning

Ms Katherine DE BIENASSIS
Health Policy Analyst, Health Division
The Organisation for Economic Cooperation and Development (OECD)

15 September 2022
THE ECONOMICS OF MEDICATION SAFETY

Katherine de Bienassis, Health Policy Analyst
15 September 2022
https://doi.org/10.1787/9a933261-en

There has been **limited progress** in improving medication safety due to a number of converging factors:

- Older populations
- Increased prevalence of chronic health conditions
- Increased medicines access and sales
- Increase in # of approved medications

> **Increased medication use**

> **Increased harms**
associated with use of medicines
The scope of medication related harms

As many as one-in-10 hospitalizations in OECD countries may be caused by a medication-related harm and…

One-in-five inpatients experience medication-related harms during hospitalization
Medication safety is a **compounding problem**

**Medication related adverse events are common in PHC and LTC**
e.g. pooled prevalence of MRAE in PHC is 8.32%

**Discharge processes are prone to medication discrepancies**
e.g. 14.1% of patients experience 1 or more medication discrepancies post-hospitalization

**Patients leave hospitalisation with increased prescriptions**
e.g. average of 1.8 new prescriptions per patient discharge

**# of discharge medications significantly related to thirty-day readmission**

**Medication errors and events can lead to a significant proportion of hospitalisations**
e.g. 3.5% of all hospital stays are caused by an ADR

**Hospitalised Patients are at high risk of experiencing an MRAE**
e.g. 1.6 to 41.4%.

**Medication-related readmissions are a significant portion of readmissions**
e.g. 21% of hospital readmissions are drug-related, 69% of these are preventable

**Hospitalisation**

**Readmission**

**Primary or long-term care**

---

Source: Authors using data from [Cano and Rozenfeld, 2009][21]; Bouvy, De Bruin and Koopmanschap, 2015[22]; Wolfe et al., 2018[23]; El Morabet et al., 2018[24]; Coleman et al., 2005[25]; Picker et al., 2015[26]; Elson, Cook and Blenkinsopp, 2017[27]; Gurwitz et al., 2005[28]. Inspired by similar figure in (Roughead, Semple and Rosenfeld, 2016[18]) and based on a template developed by Eliana Barrenho.
Total cost to OECD countries > **USD 54 billion** annually; ≈ **11% of total pharmaceutical spending**

**Six million hospital admissions** annually are the result of adverse medication reactions

Costing OECD health systems over **USD 50 billion**

Equivalent to 3% of all spending on hospital inpatient care

Medication related harms are experienced by an additional **one million hospitalised patients**, causing 3 million avoidable hospital days

Costing an additional USD **3.4 billion**.

Hospitalisation
Scope of Drug Utilisation Review Systems in OECD Countries

70% of survived countries have systems in place to conduct drug utilisation review on a national level

<table>
<thead>
<tr>
<th>Linkage to adverse medication event reporting</th>
<th>Health outcomes (e.g. eHR)</th>
<th>Diagnostic data (e.g. eHR)</th>
<th>Mortality data (e.g. census)</th>
<th>Hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costa Rica</td>
<td>Estonia</td>
<td>Italy</td>
<td>Austria</td>
<td>Australia</td>
</tr>
<tr>
<td>Norway</td>
<td>Italy</td>
<td>Luxembourg</td>
<td>Estonia</td>
<td>Canada</td>
</tr>
<tr>
<td>Norway</td>
<td>Latvia</td>
<td>Slovenia</td>
<td>Italy</td>
<td>Japan</td>
</tr>
<tr>
<td>Norway</td>
<td>Luxembourg</td>
<td>Turkey</td>
<td>Latvia</td>
<td>Latvia</td>
</tr>
<tr>
<td>Norway</td>
<td>United States</td>
<td>United States</td>
<td>Norway</td>
<td>Norway</td>
</tr>
<tr>
<td>United States</td>
<td>United States</td>
<td>United States</td>
<td>United States</td>
<td>United States</td>
</tr>
</tbody>
</table>

Note: N=20 responding countries, Countries may be counted in multiple categories. In Italy data are linkable at the regional level only. Source: OECD survey on the assessment of the adoption of systems and interventions to improve medication safety, 2022
## Use of DUR data for provider feedback, quality improvement, and policy purposes

<table>
<thead>
<tr>
<th>Domain</th>
<th>Use of DUR data</th>
<th>Implementing Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinician/prescriber feedback</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinician-level alert system</td>
<td>Estonia, Republic of Korea, Netherlands, United States</td>
<td>Costa Rica, Netherlands, Portugal, United States, Turkey</td>
</tr>
<tr>
<td>Practice-level prescribing</td>
<td>Estonia, Republic of Korea, Netherlands, United States, Turkey</td>
<td>Costa Rica, Netherlands, Portugal, United States, Turkey</td>
</tr>
<tr>
<td>Individual clinician prescribing</td>
<td>Estonia, Japan, Republic of Korea, Netherlands, United States, Turkey</td>
<td>Estonia, Netherlands, Portugal, United States</td>
</tr>
<tr>
<td>Real time dispensing decision support for pharmacists</td>
<td>Estonia, Netherlands, Republic of Korea, United States</td>
<td>Estonia, Netherlands, Republic of Korea, United States</td>
</tr>
<tr>
<td>Facilitates interactions between clinicians and pharmacists/others</td>
<td>Estonia, Netherlands, Portugal, United States</td>
<td>Estonia, Netherlands, Portugal, United States</td>
</tr>
<tr>
<td><strong>Quality improvement</strong></td>
<td>老虎:Local practice guidelines for prescribing</td>
<td>Costa Rica, Estonia, Netherlands, Portugal</td>
</tr>
<tr>
<td>Professional standards</td>
<td>Estonia, Norway, Italy, Republic of Korea, Netherlands, Portugal, United States</td>
<td>Netherlands, Portugal, Luxembourg</td>
</tr>
<tr>
<td>Practice performance indicators</td>
<td>Estonia, Norway, Italy, Republic of Korea, Netherlands, Portugal, United States</td>
<td>Estonia, Norway, Italy, Republic of Korea, Netherlands, Portugal, United States</td>
</tr>
<tr>
<td>Audit studies</td>
<td>Estonia, Netherlands, Portugal</td>
<td>Estonia, Netherlands, Portugal</td>
</tr>
<tr>
<td>Structured dialogue between clinicians and pharmacists</td>
<td>Netherlands, Portugal, United States</td>
<td>Estonia, Norway, Netherlands, Portugal, United States</td>
</tr>
<tr>
<td>Linked to clinical care guideline development and evaluation</td>
<td>Estonia, Norway, Netherlands, Portugal, United States</td>
<td>Estonia, Norway, Netherlands, Portugal, United States</td>
</tr>
<tr>
<td><strong>Policy Purposes</strong></td>
<td>Reimbursement coverage decisions</td>
<td>Estonia, Germany, Norway, Italy, Portugal, Australia, Republic of Korea, Luxembourg</td>
</tr>
<tr>
<td>Formulary inclusion</td>
<td>Costa Rica, Italy, Japan, Portugal, Luxembourg</td>
<td>Costa Rica, Luxembourg, Switzerland</td>
</tr>
</tbody>
</table>

1. The “rate of prevention of overlapping prescription” was implemented in 2020 as a patient safety indicator from Indicators for the Healthcare Quality Evaluation Grant initiative of Korea National Health Insurance Program. This indicator is calculated based on DUR data.

2. In principle, prescription of drugs with drug-drug interactions and age and pregnancy contraindications are not reimbursed (under the NHI). If these drugs were medically necessary, the reasons for prescription and dispensing must be specified on the claim, and the appropriateness of the claim will be verified.
# Digitization and medication safety initiatives by level of adoption by country

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Nationally</th>
<th>Sub-nationally/ Regionally</th>
<th>In selected care settings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adoption of digital technologies</strong></td>
<td>11</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td><strong>Patient and prescriber focused medication safety initiatives</strong></td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td><strong>Adoption of systems-level interventions</strong></td>
<td>1</td>
<td>4</td>
<td>11</td>
</tr>
</tbody>
</table>

- Barcode medication administration
- Smart infusion pumps for intravenous infusions
- Automated dispensing cabinets for high-risk medications
- Prescriber access to patients’ medical history
- Public education campaigns
- Audit and feedback mechanisms for prescribers
- Patient-reported safety measures of medication safety
- Patient access to a list of prescribed medicines
- Regular medication reviews for select patient groups
- List of high-alert medications
- Non-voluntary reporting methods using trigger tools
To improve medication safety, countries can:

- Enhance real-time information sharing and patient access to data
- Build on the expanded roles of pharmacies and pharmacists
- Strengthen pharmacovigilance and drug utilization review systems
- Promote good prescribing practices and invest in ePrescribing systems
- Capture patient experience of medication-related harms and medication side-effects
- Evaluate and calibrate the implementation of new medication safety strategies
THANK YOU AND STAY SAFE
Message on World Patient Safety Day 2022 from the WHO Regional Office for the Americas

Dr Carissa F. ETIENNE
WHO Regional Director for Americas

15 September 2022
PANEL discussion: “Medication safety: how to get better faster”

Sir Liam DONALDSON
WHO Envoy for Patient Safety

Dr Aquiles Rodrigo HENRIQUEZ
General Coordinator of Strategic Development
Ministry of Public Health
Ecuador

Ms Helen HASKELL
Patient Safety Champion
Mothers Against Medical Error

Dr Gitanjali BATMANABANE
Pro Vice-Chancellor (Medical Sciences)
GITAM Institute of Medical Sciences & Research Visakhapatnam
INDIA

Mr Joe KIANI
Founder and Immediate Past Chairman
Patient Safety Movement Foundation
Co-Chair, Patient Safety Working Group US President’s Council of Advisors on Science and Technology (PCAST)

Dr Michael COHEN
President Emeritus
Institute for Safe Medication Practices (ISMP)
USA and Chairperson, International Medication Safety Network (IMSN)
Message on World Patient Safety Day 2022 from the WHO Regional Office for the South-East Asia

Dr Poonam Khetrapal SINGH
WHO Regional Director for South-East Asia

15 September 2022
Closing session
Message on World Patient Safety Day 2022 from WHO Director-General

Dr Tedros Adhanom GHEBREYESUS
WHO Director-General

15 September 2022
Key messages and conclusion

Sir Liam DONALDSON
WHO Envoy for Patient Safety

Dr Neelam DHINGRA
Unit Head
Patient Safety Flagship
WHO headquarters

15 September 2022
Closing remarks

Dr Rudi Eggers
Director
Integrated Health Services (IHS)
WHO headquarters

15 September 2022